Company Profiles

driven by the PitchBook Platform

Ataxion

Description

Developer of novel small-molecule therapeutics designed for neurological diseases. The company's novel small-molecule therapeutics offers a treatment of hereditary ataxia based on ion-channel modulators, enabling patients to treat ataxia associated with other degenerative neurological disorders including multiple sclerosis and huntington's disease.

2013

Founded

PRIVATE

Status

M&A

Latest Deal Type

$17M

Total Amount Raised

2

Investors

Description

Developer of novel small-molecule therapeutics designed for neurological diseases. The company's novel small-molecule therapeutics offers a treatment of hereditary ataxia based on ion-channel modulators, enabling patients to treat ataxia associated with other degenerative neurological disorders including multiple sclerosis and huntington's disease.

Website:

www.ataxiontherapeutics.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

400 Technology Square 10th Floor Cambridge, MA 02139United States +1 (617) 588-2644
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Ataxion's full profile, request a free trial.

    Ataxion Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Ataxion Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Ataxion Investors (2)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Atlas VentureVenture CapitalMinority000 0000000 0000
    BiogenPE-Backed CompanyMinority000 0000000 0000
    Atlas Venture Venture Capital
    Biogen PE-Backed Company

    Ataxion Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    Michael CurtisChief Development Officer
    Martin Jefson Ph.DChief Scientific Officer
    David Grayzel MDCo-Founder, Chief Executive Officer & Board Member
    Michael Curtis Chief Development Officer
    Martin Jefson Ph.D Chief Scientific Officer
    David Grayzel MD Co-Founder, Chief Executive Officer & Board Member

    Ataxion Board Members (6)

    NameRepresentingRoleSinceContact
    Info
    Claus Braestrup MDSelfBoard Member000 0000
    David Grayzel MDSelfCo-Founder, Chief Executive Officer & Board Member000 0000
    Franz Hefti Ph.DSelfBoard Member000 0000
    Jean-François Formela MDAtlas VenturePartner000 0000
    Jo Viney Ph.DBiogenSenior Vice President, Drug Discovery000 0000
    Claus Braestrup MD Board Member Self
    David Grayzel MD Co-Founder, Chief Executive Officer & Board Member Self
    Franz Hefti Ph.D Board Member Self
    Jean-François Formela MD Partner Atlas Venture
    Jo Viney Ph.D Senior Vice President, Drug Discovery Biogen
    Request full access to PitchBook